## Clinical Context This patient has achieved complete metabolic response (CMR) after standard chemotherapy for early-stage cHL. The Deauville score of 1 (no uptake above mediastinal blood pool) indicates excellent treatment response and predicts favorable long-term outcome. ## Post-Treatment Management in cHL with CMR **Key Point:** Patients with complete metabolic response (Deauville score 1–2) after chemotherapy for early-stage cHL do NOT require consolidation radiotherapy or salvage therapy. Observation with clinical surveillance is the standard of care. **High-Yield:** Modern risk-adapted treatment in cHL emphasizes de-escalation: patients achieving CMR after chemotherapy have excellent prognosis (>95% 5-year PFS) and do not benefit from additional therapy. ### Rationale for Observation 1. **CMR predicts excellent outcome** — Deauville score 1–2 after chemotherapy is associated with >95% 5-year PFS in early-stage cHL 2. **Avoids late toxicity** — omitting radiotherapy reduces risk of secondary malignancies, cardiac dysfunction, and pulmonary fibrosis 3. **No role for consolidation in CMR** — ASCT is reserved for chemotherapy-refractory or relapsed disease, not for responding patients 4. **Salvage therapy unnecessary** — escalated chemotherapy or DHAP are indicated only for progressive disease or relapse, not for CMR ### Surveillance Strategy - **Clinical examination** — every 3 months for first 2 years, then every 6 months - **Repeat imaging** — PET-CT at 6 months post-treatment only if clinically indicated (new symptoms, rising tumor markers); routine surveillance imaging is not recommended - **Long-term follow-up** — annual clinical assessment for ≥5 years to detect relapse or late toxicities **Clinical Pearl:** The paradigm shift in cHL management is toward "response-adapted" therapy: de-escalation in chemotherapy-responsive patients (CMR) and escalation only in non-responders. This maximizes cure while minimizing late effects. ## Why Not the Other Options? | Option | Why Incorrect | |--------|---------------| | IFRT after CMR | Radiotherapy consolidation is not indicated in patients with CMR after chemotherapy. It increases late toxicity without improving PFS and is considered over-treatment. | | Salvage chemotherapy (BEACOPP/DHAP) | Salvage regimens are reserved for chemotherapy-refractory or relapsed disease. A patient in CMR does not require salvage therapy; it is unnecessary and harmful. | | ASCT | Autologous stem cell transplantation is indicated only for chemotherapy-refractory disease or relapse, not for primary therapy in responding patients. ASCT in CMR patients offers no benefit. | [cite:Harrison 21e Ch 104]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.